Merck Gets China Nod on HPV Shot for Men

Merck's HPV vaccine gets China approval for men amid declining sales
Merck's human papillomavirus vaccine has been approved for men in China, it said on Wednesday, providing the U.S. drugmaker a much-needed boost in a key market where demand has been falling among women.
Merck Gets China Nod on HPV Shot for Men Amid Sales Slump
China’s drug regulator approved Merck & Co.’s blockbuster HPV vaccine for use by men, opening a new untapped market for the US drug giant after a rush among women to get the shot lost steam.
Gardasil Gains Ground: Merck's HPV Vaccine for Men Approved in China
Merck's Gardasil vaccine, previously only available to women, has now been approved for men in China. This approval may help Merck overcome declining sales due to weak demand among women and disruptions caused by China's anti-corruption campaign.
Merck says HPV vaccine for men approved by China's drug regulator
U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's medical products administration, providing a much-needed boost to the company in a key market.
HPV vaccine for males approved in China
US pharmaceutical company Merck & Co said on Wednesday that its four-valent human papillomavirus vaccine has been approved for men aged 9 to 26 by China's top drug regulator.
China’s WuXi Biologics to sell vaccine facility to Merck for US$500 million
WUXI Biologics Cayman will sell a vaccine facility in Ireland to Merck for about US$500 million as the Chinese company seeks to enhance its margins while continuing to navigate geopolitical tensions.
Merck’s Gardasil receives expanded approval for males in China
Merck (MRK) announced that the National Medical Products Administration of China approved Gardasil Vaccine for use in males 9-26 years of age
China's WuXi Biologics to sell Irish vaccine facility to Merck as US curbs loom
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...
WuXi Bio to Sell Vaccine Facility to Merck for $500 Million
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...
Merck rival Summit draws new buy from Truist on deal prospects
Summit Therapeutics (SMMT) stock received a new buy rating from Truist based on its deal-forming prospects in oncology. Read ...
Merck says its HPV vaccine for men was approved by China's drug regulator
U.S. drugmaker Merck & Co said on Wednesday (January 8, 2025) that its human papillomavirus (HPV) vaccine for men has been ...